Description: Discuss inforce management techniques that go beyond the traditional methods of adjusting nonguaranteed elements within contractual limits during this webcast. Key methods reviewed include retention, cross-selling/up-selling, wellness, exchange programs and other customer behavior initiatives. Throughout this session, you'll be able to identify methods of inforce management beyond NGE management. You'll also understand the regulatory, legal, operational and financial considerations that will assist with the decision of pursuing this type of management.

Description: Update on IFRS 17 including news, how IFRS 17 is impacting companies financials, comparisons to LDTI, and KPIs.

Description: The Society of Actuaries (SOA) is pleased to bring you information about the actuarial career path in life insurance and predictive analytics. We’ll continue to share more about actuaries who are tackling some of the industry's biggest challenges and top employers in life insurance.

Description: Presenters will discuss difficulties within the new NAIC ESG, such as how the model deals with interest rate flooring and its treatment of the linkage between equity and treasury bond returns. They will also discuss the documentation and governance process surrounding the new NAIC ESG.

Description: This session will cover the treatment of various forms of reinsurance under Valuation Manual-20 (VM-20). Speakers will discuss the implications of various types of reinsurance agreements on the calculation of principle-based reserves (PBR). This will include coinsurance and modified coinsurance, guaranteed and non-guaranteed yearly renewable term (YRT), as well as financial reinsurance. Additionally, practical considerations for PBR in 2024+ will be discussed including adopted and active APF's, their content, and emerging issues.

Description: At the end of December 2020, Congress enacted the Consolidated Appropriates Act, 2021, which included revisions to Section 7702. Effective for policies issued after December 31, 2020, the fixed 4% and 6% minimum annual effective rates under these tests were changed to refer to a market-based rate called the “insurance interest rate”. For contracts issued in 2021, the insurance rate was set to 2% - defined as the lower of the Section 7702 applicable federal interest rate based on the 60-month period ending December 2019 (2%) and the Section 7702 valuation interest rate in effect for 2020 (3.5%). This reduction in the rates used for compliance testing required significant product, operational, and technology changes for companies to reach product compliance. After 2021, the insurance interest rate is redetermined annually with a minimum change floor.

Description: Indexed Universal Life ('IUL') has commanded a substantial share of life insurance sales since it was first introduced nearly 25 years ago. Even today, despite rising interest rates, IUL remains popular. It was one of the only products whose sales grew in 2022. Today's IUL products bear only passing resemblance to those offered when the product was first introduced, with updates to product design driven by regulatory and economic changes.

Description: Stay current with the latest mortality trends and practices in this wide-ranging session, covering research performed by the SOA and their collaborators, including recent research from the SOA's Individual Life Experience Committee. Topics will include mortality improvement, mortality by socioeconomic category, cause of death analysis, and insurance company life experience quintile analysis.

Description: How do you go about designing a new product? Behavioral Science is an often overlooked tool in enhancing product design and using a Discrete Choice Experiment (DCE) can give you insights to customer preferences and their willingness to pay for features. The result of this work is a product explicitly designed with your customers and market in mind.

Description: Join us for a lively discussion on how accelerated underwriting (AU) practices have evolved over time and specifically because of COVID-19.